Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott, GlaxoSmithKline personal medicine collaboration

This article was originally published in The Gray Sheet

Executive Summary

The diagnostic and pharmaceutical companies said March 3 they will collaborate to develop a molecular diagnostic test to help determine which patients could benefit from a skin cancer treatment under development at GlaxoSmithKline. The companion pharmaceutical product under development is GSK's MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic). The diagnostic, a polymerase chain reaction test, would screen patients to see whether they have MAGE-A3 expressing melanoma tumors. The test would run on the Abbott m2000 automated molecular instrument system. The companies plan to seek regulatory approval in the U.S. and Europe. In July 2009, the companies announced a similar collaboration for the MAGE-3 marker in non-small-cell lung cancers (1"The Gray Sheet" July 20, 2009)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel